ERBB2 and breast carcinoma: A recent case series looking at the management of nausea and vomiting in 10 patients receiving T-DXd treatment of HER2-positive breast cancer found that the rate of nausea and vomiting was 28.9% (13 of 45 doses) when patients were managed using a moderate-emetic-risk protocol, with all events being grade 1 or 2.